SNCA and Parkinson disease: Pathological markers, such as amyloid-beta and tau in Alzheimer’s, alpha-synuclein in Parkinson’s, and polyglutamine in Huntington’s, pose a major challenge to the development of effective diagnostic and treatment methods for neurological disorders.